Fig. 6

LOX improved the aggressiveness of GC. A Expression level of LOX in GC tissues from the TCGA database. B Expression level of LOX in GC cells and normal epithelial cell line GES-1. C IHC analysis of LOX in GC tissue and adjacent normal tissue. D Western blot analysis of the efficiency of LOX-specific siRNA in GC cells. E, F Effect on cellular migration and invasion by downregulating LOX in MKN45 (E) and AGS cells (F). Scale bar = 100 μm. G, H Silencing LOX in MKN45 (G) and AGS (H) cells inhibited the tube-formation rate of HUVECs. Scale bar = 200 μm. I Western blot analysis of the expression of EMT markers and VEGFA in LOX-knockdown group or control group. J LOX-targeting shRNA was used. K Representative images of blood vessel formation to plugs (left panel) and skin vasculatures around the plugs (right panel). L IHC staining of CD31 to plug sections as indicated and the microvascular density (MVD) values for each group. Scale bars = 100 μm. M Detection of cell growth by CCK8 assays in treated MKN45 and AGS cells. Data were analyzed using two-way ANOVA. N Representative images of gross appearance of subcutaneous tumors from nude mice. Error bars, mean ± SD from triplicate samples. *P < 0.05, **P < 0.01, ***P < 0.001 by Student’s t‐test unless otherwise specified